Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

255
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
255
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.4K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.4K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

626
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
626
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

313
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
313
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.9K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A giant exoplanet orbiting a very-low-mass star challenges planet formation models.

Science (New York, N.Y.)·2019
Same author

Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment.

European review for medical and pharmacological sciences·2014
Same author

Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1.

Journal of viral hepatitis·2014
Same author

IL28B genetic variation and hepatitis C virus-specific CD4(+) T-cell responses in anti-HCV-positive blood donors.

Journal of viral hepatitis·2012
Same author

Reversal of nonstructural protein 3-specific CD4(+) T cell dysfunction in patients with persistent hepatitis C virus infection.

Journal of viral hepatitis·2012
Same author

Femtosecond laser microstructuring of zirconia dental implants.

Journal of biomedical materials research. Part B, Applied biomaterials·2010
Same journal

Effectiveness of cardiac Holter monitoring for more than four weeks for the detection of occult atrial fibrillation in embolic stroke of undetermined source.

Medicina clinica·2026
Same journal

Artificial intelligence in surgical training and education: a narrative review.

Medicina clinica·2026
Same journal

Treatment of phantom limb syndrome with ketamine.

Medicina clinica·2026
Same journal

Comment on "Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis".

Medicina clinica·2026
Same journal

Limitations in the interpretation of thyroid function tests.

Medicina clinica·2026
Same journal

Cerebrotendinous xanthomatosis without neurological manifestations: An atypical form with normal cholestanol levels.

Medicina clinica·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K

[Non-A non-B hepatitis]

R Esteban, J Guardia

    Medicina Clinica
    |November 19, 1983
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
    09:02

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

    Published on: June 5, 2020

    7.9K
    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    14.0K

    Related Experiment Videos

    Last Updated: Feb 14, 2026

    Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
    07:10

    Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

    Published on: June 18, 2020

    22.9K
    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
    09:02

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

    Published on: June 5, 2020

    7.9K
    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    14.0K